Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors

doi:10.3760/cma.j.issn.1673-422X.2017.06.014

Abstract

Abstract: Hypoxia inducible factor1α (HIF1α)vascular endothelial growth factor (VEGF)vascular endothelial growth factor receptor2 (VEGFR2) signaling pathway plays a vital role in the regulation of neovascularization, and the activation of this pathway is closely related with tumor invasion and metastasis.

Key words: Neoplasms, Neovascularization, pathologic, Vascular endothelial growth factors, Receptors, vascular endothelial growth factor, Signal transduction

Sun Fei, Wang Jianlin, Yu Jingping. Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 456-.

References

［1］ Jung HJ, Kim Y, Ju YS, et al. Antiangiogenic activity of herboxidiene via downregulation of vascular endothelial growth factor receptor2 and hypoxiainducible factor1α［J］. Arch Pharm Res, 2015, 38(9): 1728-1735. DOI: 10.1007/s1227201506254. ［2］ Park MH, Choi KY, Jung Y, et al. Phospholipase D1 protein coordinates dynamic assembly of HIF1αPHDVHL to regulate HIF1α stability［J］. Oncotarget, 2014, 5(23): 11857-11872. ［3］ Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells 1［J］. Bioch Pharmacol, 2001, 61(8): 947-954. ［4］ Zhu H, Feng Y, Zhang J, et al. Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma［J］. Cancer Biol Ther, 2011, 11(11): 981-987. ［5］ Zhao T, Zhu Y, Morinibu A, et al. HIF1mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs［J］. Sci Rep, 2014, 4: 3793. DOI: 10.1038/srep03793. ［6］ Ikezawa Y, SakakibaraKonishi J, Mizugaki H, et al. Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer［J］. Int J Clin Oncol, 2017, 22(1): 59-69. DOI: 10.1007/s1014701610318. ［7］ Srinivasan B, Johnson TE, Xing C. Chalconebased inhibitors against hypoxiainducible factor 1—structure activity relationship studies［J］. Bioorg Med Chem Lett, 2011, 21(1): 555-557. DOI: 10.1016/j.bmcl.2010.10.063. ［8］ Wang L, Chen G, Lu X, et al. Novel chalcone derivatives as hypoxiainducible factor (HIF)1 inhibitor: synthesis, antiinvasive and antiangiogenic properties［J］. Eur J Med Chem, 2015, 89: 88-97. DOI: 10.1016/j.ejmech.2014.10.036. ［9］ Wang LH, Jiang XR, Yang JY, et al. SYP5, a novel HIF1 inhibitor, suppresses tumor cells invasion and angiogenesis［J］. Eur J Pharmacol, 2016, 791: 560-568. DOI: 10.1016/j.ejphar.2016.09.027. ［10］ Grothey A. VEGF inhibition beyond tumour progression［J］. Lancet Oncol, 2013, 14(1): 2-3. DOI: 10.1016/S14702045(12)705168. ［11］吴军, 王婧, 曹邦伟. 抗肿瘤血管生成药物不良反应的发生机制及处理［J］. 医学综述, 2016, 22(16): 3154-3157. DOI: 10.3969/j.issn.10062084.2016.16.010. ［12］ Martín M, Loibl S, Von MG, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as firstline treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study［J］. J Clin Oncol, 2015, 33(9): 1045-1052. DOI: 10.1200/JCO.2014.57.2388. ［13］ Flaherty KT, Manola JB, Pins M, et al. Best: a randomized phase Ⅱ study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma—a trial of the ECOGACRIN Cancer Research Group (E2804)［J］. J Clin Oncol, 2015, 33(21): 2384-2391. DOI: 10.1200/JCO.2015.60.9727. ［14］ Chong DQ, Manalo M, Imperial M, et al. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer［J］. Asia Pac J Clin Oncol, 2016, 12(3): 275-283. DOI: 10.1111/ajco.12496. ［15］ Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase Ⅲ randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen［J］. J Clin Oncol, 2012, 30(28): 3499-3506. ［16］ Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase Ⅱ trial of weekly topotecan with and without zivaflibercept in patients with platinumtreated smallcell lung cancer［J］. J Clin Oncol, 2014, 32(23): 2463-2470. DOI: 10.1200/JCO.2013.51.4109. ［17］ Liu F, Liu Q, Wang G, et al. Ramucirumab in metastatic renal cell carcinoma: the sex, race, and age issues［J］. Cancer, 2014, 120(15): 2379. DOI: 10.1002/cncr.28741. ［18］ Mackey JR, RamosVazquez M, Lipatov O, et al. Primary results of ROSE/TRIO12, a randomized placebocontrolled phase Ⅲ trial evaluating the addition of ramucirumab to firstline docetaxel chemotherapy in metastatic breast cancer［J］. J Clin Oncol, 2015, 33(2): 141-148. DOI: 10.1200/JCO.2014.57.1513. ［19］ Garcia JA, Hudes GR, Choueiri TK, et al. A phase 2, singlearm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy［J］. Cancer, 2014, 120(11): 1647-1655. DOI: 10.1002/cncr.28634. ［20］ Vennepureddy A, Singh P, Rastogi R, et al. Evolution of ramucirumab in the treatment of cancera review of literature［J］. J Oncol Pharm Pract, 2016, In press. ［21］ Marotta V, Sciammarella C, Capasso M, et al. Preliminary data of VEGFA and VEGFR2 polymorphisms as predictive factors of radiological response and clinical outcome in iodinerefractory differentiated thyroid cancer treated with sorafenib［J］. Endocrine, 2016, In press. DOI: 10.1007/s1202001612006. ［22］ Ibrahim N, Yu Y, Walsh WR, et al. Molecular targeted therapies for cancer: sorafenib monotherapy and its combination with other therapies (review)［J］. Oncol Rep, 2012, 27(5): 1303-1311. DOI: 10.3892/or.2012.1675. ［23］ Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer［J］. Front Endocrinol (Lausanne), 2015, 6: 176. DOI: 10.3389/fendo.2015.00176. ［24］ Qu Z, Wu J, Wu J, et al. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro［J］. J Exp Clin Cancer Res, 2016, 35(1): 159. ［25］ Oh WK, McDermott D, Porta C, et al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review［J］. Int J Oncol, 2014, 44(1): 5-16. DOI: 10.3892/ijo.2013.2181. ［26］ Ibrahim EM, Kazkaz GA, Abouelkhair KM, et al. Sunitinib adverse events in metastatic renal cell carcinoma: a metaanalysis［J］. Int J Clin Oncol, 2013, 18(6): 1060-1069. DOI: 10.1007/s1014701204972. ［27］ Pokuri VK, Tomaszewski GM, AitOudhia S, et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): phase Ⅱ trial［J］. Am J Clin Oncol, 2016, In press. ［28］ Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase Ⅲ trial［J］. J Clin Oncol, 2013, 31(32): 4067-4075. DOI: 10.1007/s1014701204972. ［29］ Li J, Qin S, Xu J, et al. Randomized, doubleBlind, placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapyrefractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454. DOI: 10.1200/JCO.2015.63.5995. ［30］ Lee HJ, Ji YM, Baek SW. Is treatmentemergent toxicity a biomarker of efficacy of apatinib in gastric cancer?［J］. J Clin Oncol, 2016, 34(31): 3823. DOI: 10.1200/JCO.2016.68.8663. ［31］ Carr BI, Cavallini A, Lippolis C, et al. FluoroSorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery［J］. J Cell Physiol, 2013, 228(2): 292-297. DOI: 10.1002/jcp.24148. ［32］ Kim J, Ulu A, Wan D, et al. Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy［J］. Mol Cancer Ther, 2016, 15(5): 890-898. DOI: 10.1158/15357163.MCT150847. ［33］ Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebocontrolled phase Ⅱ trial［J］. J Clin Oncol, 2016, 4(23): 2728-2735. DOI: 10.1200/JCO.2015.65.1901.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.